ストックスクリーナーアプリを入手
2.43
0.41%
0.01
Fortress Biotech Inc (FBIO) 最新ニュース
Aug Spikes: Is Fortress Biotech Inc part of any ETFPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Growth Value: How does Fortress Biotech Inc score in quality rankingsDay Trade & High Conviction Investment Ideas - baoquankhu1.vn
Sectors Review: Should value investors consider Fortress Biotech Inc2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Liquidity Mapping Around (FBIOP) Price Events - Stock Traders Daily
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Maintains Target Price $4.5 - Moomoo
Institution Moves: Does Fortress Biotech Inc stock benefit from AI growth2026 Volume Leaders & Risk Controlled Daily Trade Plans - baoquankhu1.vn
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fortress Biotech Inc (FBIO) Stock Price, Trades & News - GuruFocus
FBIO PE Ratio & Valuation, Is FBIO Overvalued - Intellectia AI
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
FBIO SEC FilingsFortress Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS - MarketBeat
Fortress Biotech: Q4 Earnings Snapshot - Barchart.com
Fortress Biotech 2025 10-K: Revenue $63.3M, GAAP net loss $(32.9)M - TradingView
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) boosts cash with PRV sale, royalties - Stock Titan
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
Fortress Biotech Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView — Track All Markets
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M - National Today
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital - TipRanks
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale - Stock Titan
Cyprium Therapeutics sells rare disease priority review voucher for $205 million - StreetInsider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes - GlobeNewswire
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Bitget
Why (FBIOP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aug Spikes: How do insiders feel about Fortress Biotech IncFed Meeting & Expert Curated Trade Ideas - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - marketbeat.com
Fortress Biotech Inc Stock: Business Model, Pipeline Progress, and Investor Considerations in Biotec - AD HOC NEWS
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm - AD HOC NEWS
Portfolio Recap: How does Fortress Biotech Inc score in quality rankingsOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Portfolio Shifts: Can Fortress Biotech Inc deliver alphaQuarterly Earnings Summary & Smart Money Movement Alerts - baoquankhu1.vn
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Buyback Watch: How liquid is Fortress Biotech Inc stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A - Stock Titan
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after the market closes on March 25. - 富途牛牛
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview - Minichart
Mustang Bio (NASDAQ: MBIO) details GBM pipeline, Orphan status and cash - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Understanding Momentum Shifts in (FBIOP) - Stock Traders Daily
Macro Review: How do insiders feel about Fortress Biotech IncMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewswire
Quarterly Earnings: Should value investors consider Fortress Biotech Inc2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Fortress Biotech Inc Stock (ISIN: US32015L1035) Faces Short Interest Pressure Amid Biotech Sector Vo - AD HOC NEWS
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Swing Trade: How do insiders feel about Fortress Biotech IncCEO Change & Daily Technical Forecast Reports - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (FBIOP) Movement - Stock Traders Daily
Aug Sectors: How do insiders feel about Fortress Biotech IncMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Aug Opening: What are the risks of holding Fortress Biotech IncJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):